Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться

Sanofi

Специалисты компании

Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.

Пока никто не показал здесь свою визитку.

Работаете здесь? Покажите свою визитку: фото, должность, кнопка «Написать». Почту и телефон не показываем. Только с вашего разрешения, убрать можно в любой момент. Я здесь работаю — показать мою визитку

Нашли ошибку или чужую визитку? Сообщить модератору

2
исследования идут сейчас
123
исследования в базе
112
Россия · идут 2
8
Беларусь
3
Казахстан

Разрешения по годам

Новые препаратыБиоэквивалентность

Фазы

Фаза II 15
Фаза II–III 6
Фаза III 86
Фаза IV 11

Области

Пока нет данных

Завершено Фаза III Россия
SAR153191 (REGN88) · Sanofi

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

2 023 участника во всех странах ClinicalTrials.gov LTS11210
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo · Sanofi

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

6 068 участников во всех странах ClinicalTrials.gov EFC11319
Завершено Фаза III Россия
larotaxel (XRP9881); gemcitabine; cisplatin · Sanofi

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

337 участников во всех странах ClinicalTrials.gov EFC6668
Завершено Фаза IV Россия
Insulin glargine; Insulin Detemir · Sanofi

Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.

Москва 1 центр 973 участника во всех странах ClinicalTrials.gov LANTU_C_00579
Завершено Фаза III Россия
clopidogrel (SR25990) · Sanofi

A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.

15 603 участника во всех странах ClinicalTrials.gov EFC4505
Завершено Фаза III Россия
Levofloxacin; Piperacillin/Tazobactam · Sanofi

An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatment of Mild to Moderate Hospital-Acquired Pneumonia Adult Patients in Both General Wards and ICU (Intensive Care Unit)

Москва 1 центр 460 участников во всех странах ClinicalTrials.gov HR355_3035
Завершено Фаза IV Россия
Levofloxacin · Sanofi

Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)

Москва 1 центр 100 участников во всех странах ClinicalTrials.gov LEVOF_L_00972
Завершено Фаза II Россия
Otamixaban (XRP0673); unfractionated heparin; eptifibatide · Sanofi

A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy

3 241 участник во всех странах ClinicalTrials.gov DRI6624
Завершено Фаза II–III Россия
SR48692 · Sanofi

A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide

432 участника во всех странах ClinicalTrials.gov EFC3679
Завершено Фаза II Россия
SSR125543; escitalopram; placebo · Sanofi

An Eight-week, Multinational, Multicenter, Double-blind, Active- and Placebo-controlled Clinical Trial Evaluating the Efficacy and Tolerability of Three Fixed Doses of SSR125543 (20 mg Daily, 50 mg Daily and 100 mg Daily) in Outpatients With Major Depressive Disorder

580 участников во всех странах ClinicalTrials.gov DFI5687
Завершено Фаза III Россия
Clopidogrel; placebo · Sanofi

Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age

49 участников во всех странах ClinicalTrials.gov LTS10916
Завершено Фаза IV Россия
INSULIN GLULISINE; INSULIN GLARGINE · Sanofi

A Study of Effectiveness and Safety of Apidra in Combination With Lantus Therapy in Basal-bolus Insulin Regimen in Inadequately Controlled Children and Adolescents With Type 1 Diabetes in the Russian Federation.

100 участников во всех странах ClinicalTrials.gov APIDR_L_04884
Завершено Фаза II Россия
Hexadecasaccharide (SR123781A) · Sanofi

A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)

Москва 1 центр 1 257 участников во всех странах ClinicalTrials.gov DRI5228
Завершено Фаза III Россия
SR58611A · Sanofi

A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A (350mg q12)

704 участника во всех странах ClinicalTrials.gov LTE5376
Прекращено Фаза III Россия
clopidogrel (SR25990C) · Sanofi

A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation

6 706 участников во всех странах ClinicalTrials.gov EFC4912 W
Завершено Фаза II–III Россия
SR123781A · Sanofi

A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Москва 1 центр 1 090 участников во всех странах ClinicalTrials.gov DRI5664
Завершено Фаза II Россия
Celivarone; Amiodarone; Matching placebo · Sanofi

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death

486 участников во всех странах ClinicalTrials.gov DRI10936
Завершено Фаза III Россия
Doxorubicin; Cyclophosphamide; Docetaxel; Herceptin; Carboplatin · Sanofi

Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration

3 222 участника во всех странах ClinicalTrials.gov TAX_GMA_302
Завершено Фаза III Россия
Docetaxel (TAXOTERE®) Chemotherapy; Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Docetaxel (TAXOTERE®) Chemotherapy; Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Leuprolide acetate ( ELIGARD®) Hormonal Therapy · Sanofi

A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- Leuprolide Acetate) in Combination With TAXOTERE® (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy

228 участников во всех странах ClinicalTrials.gov XRP6976J_3501

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.